All In Biotech

Drug Trial Radar · NCT02411695

Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

A Phase 1, Multicenter, Open-label, Dose-Escalation Trial to Assess the Safety, Tolerability and Pharmacokinetics of Oral Brexpiprazole (OPC- 34712) in Adolescents With Schizophrenia

Last checked: Nov 20, 2026Latest source record: Apr 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

43

Actual

Start

Mar 2015

Primary completion

Jan 1, 2017

Study completion Jan 1, 2017

Sponsor

Sponsor type
Industry
Collaborators
H. Lundbeck A/S
First posted
Apr 8, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 13 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of oral brexpipirazole in adolescent subjects with schizophrenia or Other Related Psychiatric Disorders.

Conditions

  • Schizophrenia

Interventions

  • Brexpiprazole (OPC-34712)Drug

    Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule. The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase. Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Reported Adverse Events (AEs) at 30 day Follow-UpTime frame: 30 day Follow-Up
  2. Change from Baseline to Day 17 in Vital SignsTime frame: Baseline to Day 17
  3. Change from Baseline to Day 17 ECGsTime frame: Baseline to Day 17
  4. Change from Baseline to Day 17 HematologyTime frame: Baseline to Day 17
  5. Change from Baseline to Day 14 Physical examinationTime frame: Baseline to Day 14
  6. Change from Baseline to Day 17 Body weightTime frame: Baseline to Day 17
  7. Change from Baseline to Day 17 Serum chemistryTime frame: Baseline to Day 17
  8. Change from Baseline to Day 17 UrinalysisTime frame: Baseline to Day 17
  9. Maximal peak steady-state plasma concentrationTime frame: At Day 14
  10. Minimum trough steady-state plasma concentrationTime frame: At Day 14
  11. Time to maximum peak steady-state plasma concentrationTime frame: At Day 14
  12. Area under the concentration-time curve during the dosing interval at steady-stateTime frame: At Day 14
  13. Terminal elimination half-lifeTime frame: At Day 14
  14. For Brex only, apparent cleanse and apparent volume of distributionTime frame: At Day 14

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Culver City, California

  • Site not named

    Orange, California

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Marlton, New Jersey

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    The Woodlands, Texas

  • Site not named

    Orem, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.